Laboratory Monitoring for Epclusa (Sofosbuvir/Velpatasvir)
For patients on Epclusa, obtain baseline labs before treatment, then repeat complete blood count, creatinine with calculated GFR, and hepatic function panel at week 4 of treatment, with HCV RNA testing at week 4 and at 12 weeks post-treatment to confirm cure.
During Treatment Monitoring
The AASLD-IDSA guidelines provide clear monitoring recommendations for direct-acting antiviral regimens like Epclusa 1:
Required Laboratory Tests:
At Week 4 of Treatment:
- Complete blood count
- Creatinine level with calculated GFR
- Hepatic function panel (ALT, AST, bilirubin, alkaline phosphatase, INR)
- Quantitative HCV RNA viral load
Additional monitoring as clinically indicated based on patient-specific factors 1.
Important Safety Monitoring:
Renal function should be checked regularly, especially in patients with reduced eGFR, as sofosbuvir requires monitoring in those with kidney impairment 2. The drug is not recommended for eGFR <30 mL/min/1.73 m² 2.
ALT monitoring at weeks 4,8, and 12 is recommended 2. Prompt discontinuation is required if there's a 10-fold increase in ALT at week 4, or any ALT increase accompanied by symptoms (weakness, nausea, vomiting, jaundice) or elevated bilirubin, alkaline phosphatase, or INR 1.
Virologic Response Monitoring
HCV RNA testing schedule 1, 3:
- Baseline (before treatment)
- Week 4 of treatment (to assess adherence and early response)
- Week 12 post-treatment (primary endpoint for sustained virologic response [SVR12])
- Optional: End of treatment and/or week 24 post-treatment
The EASL guidelines specifically recommend for IFN-free regimens like Epclusa: HCV RNA at baseline, week 2 (adherence assessment), week 4, end of treatment (week 12), and 12-24 weeks post-treatment 4, 3.
Minimal Monitoring Approach
Recent evidence supports a simplified approach: The ACTG A5360 (MINMON) trial demonstrated that minimal monitoring with sofosbuvir/velpatasvir achieved 95% SVR without scheduled on-treatment visits or laboratory monitoring, with only remote contact at week 4 for adherence 5. However, this approach is not yet standard of care and baseline assessment plus post-treatment SVR confirmation remain essential.
Post-Treatment Assessment
At 12 weeks after completing treatment (Week 24 from start):
- Quantitative HCV RNA to confirm SVR12 (undetectable = cure)
- Hepatic function panel to assess transaminase normalization 6
For patients with cirrhosis who achieve SVR:
- Continue HCC surveillance with ultrasound every 6 months indefinitely 1
- Continue endoscopic surveillance for varices 1
Special Populations
Patients on ribavirin (not standard with Epclusa but sometimes added): More frequent CBC monitoring for anemia 1, 2.
Patients on diabetes medications: Monitor for hypoglycemia 6.
Patients on warfarin: Monitor INR for subtherapeutic anticoagulation 6.
Common Pitfalls to Avoid:
- Don't skip week 4 labs—this is the critical safety checkpoint for hepatotoxicity
- Don't forget renal monitoring, especially in patients with baseline kidney disease
- Don't discontinue monitoring in cirrhotic patients after SVR—they remain at HCC risk
- Treatment should not be interrupted if HCV RNA results are delayed 1